Arthneeti

Sun Pharmaceutical Industries Q1 FY27 Share Price & Earnings Call Analysis

₹1,761.00+0.20% today
Market cap
₹4.23L Cr
P/E
33.46
ROE
15.95%
PEG
2.58
Price to sales
7.05
Debt to equity
0.06
52W high / low
₹2,001 / ₹1,589
Sales growth (5Y)
11.78%
EBITDA margin
29.79%
Net profit margin
21.31%
Promoter holding
52.68%
Sales (last year)
₹59,911 Cr

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]

Guidance scorecard · Q1 FY27 call

What Sun Pharma.Inds.'s management guided
and where it ranks in Pharmaceuticals & Biotechnology

Revenue10–20%MarginsFlatCapexWhat management saidFundraisingWhat management saidOrder bookWhat management said

RevenueQ1 FY27 call

10–20%
  • The company expects high single-digit revenue growth for the full year FY27, despite Q1 growth of about 11%.
  • Growth is driven by volume and new product introductions: in domestic market, 60% of growth comes from volume and new prescriptions.
  • Innovative medicines, both in the U.S. and international markets, continue to show healthy growth and new launches like Unloxcyt and Leqselvi are expected to gain traction over time.
  • Domestic business growth is broad-based across all therapy areas, supported by prescription growth and field force expansion especially in tier 2 and 3 cities.

2 more points from Sun Pharma.Inds.'s call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Sun Pharma.Inds. said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

  • It highlights strategic investments in R&D with consolidated investment of INR 8,264 million (5.4% of sales) in Q1 FY27, of which 30% is for innovative medicine.
  • There is mention of out-licensing partnership strategies (e.g., for MM-II product targeting orthopedic pain) due to lack of commercial presence in specific markets.
  • The acquisition of Organon is a significant strategic move, with approvals received and completion expected in Q4 FY27.

2 more points from Sun Pharma.Inds.'s call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

Ask what Sun Pharma.Inds. said on fundraising →

Full Q1 FY27 analysis

Order bookQ1 FY27 call

Ask what Sun Pharma.Inds. said on the order book →

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Sun Pharma.Inds. rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Sun Pharma.Inds..

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Sun Pharma.Inds. announcements

All announcements →

Financials of Sun Pharma.Inds.

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Sun Pharma.Inds.

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +10,93111,94112,19212,38111,98312,65313,29113,67512,95913,85114,47815,52114,612
Expenses +8,1298,6099,0138,9048,9489,0459,3529,6669,2439,5509,95110,57210,658
Operating Profit2,8023,3323,1793,4773,0353,6083,9394,0093,7164,3024,5274,9483,954
OPM %26%28%26%28%25%29%30%29%29%31%31%32%27%
Other Income +202-118294180504533354149251-35447089458
Interest938149357462695249751007886
Depreciation672651633622650655626631664701730732775
Profit before tax2,2402,4812,7913,0002,8163,4243,5983,4763,2543,1734,1684,2273,551
Tax %10%19%14%14%5%16%16%16%34%27%25%20%23%
Net Profit +1,9832,0062,3852,5612,6592,8613,0372,9132,1542,2933,1253,3812,710
EPS in Rs8.278.439.9010.5211.0611.8212.6712.108.969.5013.0014.0411.31

Financials of Sun Pharma.Inds.

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +27,39228,48731,57826,48929,06632,83833,49838,65443,88648,49752,57858,462
Expenses +19,49820,31321,47620,85822,68925,85525,02828,39732,23535,47937,46440,731
Operating Profit7,8948,17410,1025,6316,3776,9838,47010,25811,65013,01815,11417,731
OPM %29%29%32%21%22%21%25%27%27%27%29%30%
Other Income +283-42610-135-258382-3,449-3,5054598651,444664
Interest579523400518555303141127172238231339
Depreciation1,1951,0381,2651,5001,7532,0532,0802,1442,5292,5572,5752,938
Profit before tax6,4036,5719,0483,4793,8105,0102,7994,4819,40811,08813,75215,119
Tax %14%14%13%26%16%16%18%24%9%13%20%24%
Net Profit +5,4765,6587,8462,5423,2084,1722,2723,3898,5139,61010,96511,509
EPS in Rs21.9218.8929.038.7311.1115.6912.1013.6435.3239.9145.5547.84
Dividend Payout %14%5%12%23%25%25%62%73%33%34%35%33%

Financials of Sun Pharma.Inds.

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital207241240240240240240240240240240240
Reserves25,43132,74236,40038,07441,16945,02546,22347,77155,75563,42771,97883,330
Borrowings +8,9968,4979,83210,38510,5148,3153,8691,2906,8863,2742,3624,627
Other Liabilities +14,08913,94814,62415,59812,66614,61517,29120,47417,83118,38717,32820,588
Total Liabilities48,72355,42861,09564,29764,59068,19467,62269,77680,71285,32891,908108,785
Fixed Assets +12,68215,87217,67518,85321,83722,84721,55322,66524,06523,24822,58634,493
CWIP2,0392,1752,8012,4651,4111,2201,5671,2874,9735,3546,6441,381
Investments2,7161,8301,1927,1437,90310,1439,61212,84914,82415,02618,35424,723
Other Assets +31,28635,55039,42735,83733,43933,98434,89032,97536,84941,70044,32448,189
Total Assets48,72355,42861,09564,29764,59068,19467,62269,77680,71285,32891,908108,785

Financials of Sun Pharma.Inds.

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +5,6166,6867,0823,9072,1966,5556,1708,9854,95912,13514,07212,419
Cash from Investing Activity +-1,502-3,949-4,186-3,104-310-2,225407-5,556-7,220-763-5,183-11,344
Cash from Financing Activity +-1,187-1,889-2,285-1,539-2,731-5,715-5,980-5,1932,376-6,710-7,906-2,513
Net Cash Flow2,927848611-736-844-1,386596-1,7651154,662983-1,437
Free Cash Flow3,3163,3533,4922,013-9665,1055,0977,5502,8959,96412,0058,906
CFO/OP93%106%90%83%48%113%85%78%56%105%96%83%

Financials of Sun Pharma.Inds.

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days688783108112105999995859197
Inventory Days307370307338366311378315360338348363
Days Payable178207197234192142167158194194210232
Cash Conversion Cycle197251193212285274310255261229228228
Working Capital Days-737-4-3131515147405565185
ROCE %23%18%20%10%10%10%13%17%16%17%20%21%

Guidance history

How Sun Pharma.Inds.'s guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%Flat———
Q4 FY26 call →0–10%FlatPlannedPlanned—
Q3 FY26 call →10–20%FlatPlannedNone planned—
Q2 FY26 call →10–20%FlatPlannedPlanned—

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

55out of 100

Momentum score · price trend

55 out of 100 — Steady

Over the past year its share price has moved roughly in the middle of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+4.2%64%
Last 6 months−1.2%53%
Last 3 months−11.7%39%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Sun Pharma.Inds.: 0.4 × 64 + 0.4 × 53 + 0.2 × 39 = 55.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 28 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Sun Pharma.Inds.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Divi's Lab.vs Torrent Pharmaceuticals Ltdvs Laurus Labs Ltd